# Do we need phase Design for Vaccine Development and When?

## FDA Regulation for Drug Development

- Safety
  - Federal Food, Drug, and Cosmetic Act in 1938(Pub. L. No. 75-717, 52 Stat. 1040)

- Efficacy
  - The Kefauver-Harris Amendments in 1962

### Clinical Trials in Drug Development

• Phase 1- Determine a safe dose

• Phase 2- Determine a preliminary efficacy

• Phase 3- Confirm efficacy

### Phase 1


• Determine a Maximum Tolerated Dose (MTD)

The highest dose that will produce the desired effect without unacceptable toxicity

• Determine a Biological Active Dose (BAD)

The dose that will produce the desired effect on a specific molecule's function

# Do we need dose escalation trials in vaccine?



Search for cancer vaccine trials on PubMed

• Phase 1, phase 1/2, and pilot studies in therapeutic cancer vaccines

• Reported from 1990 through 2011

### Are cancer vaccines toxic?

# What is the rate of vaccine-related toxicity in relation to the number of vaccinated patients?

Vaccine trials			All Grade 3/4 Toxicities		Systemic Vaccine Related Grade 3/4 Toxicities	
Vaccine Category	No. Trials	No. Patients	No. Events	%	No. Events	%
Autologous	88	1692	37	2.19	23	1.36
DC	58	922	9	0.98	3	0.33
Tumor	30	770	28	3.64	20	2.60
Allogeneic	17	407	22	5.41	5	1.23
Synthetic	136	2853	108	3.79	35	1.23
Peptide	68	1333	40	3.00	11	0.83
DNA	17	311	1	0.32	1	0.32
RNA	2	36	0	0	0	0
Virus	31	662	23	3.47	13	1.96
Bacteria	6	126	27	21.43	7	3.97
Anti-idiotypic	10	362	15	4.14	0	0
Liposomal	2	23	2	8.70	2	8.70
TOTAL	241	4952	167	3.37	62	1.25

# What is the rate of vaccine-related toxicity in relation to the number administered vaccines?

Vaccine Trials				All Grade 3/4 Toxicities		Systemic Vaccine Related Grade 3/4 Toxicities	
Vaccine Category	No. Trials	No. Patients	No. Vaccines	No. Events	%	No. Events	%
Autologous	73	1301	5722	20	0.35	8	0.14
DC	51	796	3424	9	0.26	3	0.09
Tumor	22	505	2298	11	0.48	5	0.22
Allogeneic	16	347	1874	22	1.17	5	0.26
Synthetic	117	2376	14239	78	0.55	30	0.21
Peptide	61	1183	7637	37	0.48	9	0.12
DNA	15	259	1388	1	0.07	1	0.07
RNA	2	36	335	0	0	0	0
Virus	27	535	2365	22	0.93	13	0.55
Bacteria	4	80	530	9	1.70	5	0.94
Anti-idiotypic	7	266	1938	7	0.36	0	0
Liposomal	1	17	46	2	4.35	2	4.35
TOTAL	206	4024	21835	120	0.55	43	0.20

## Does dose escalation determine MTD?

				Trials		
Vaccine Category	No. Trials	No. Patients	No. Trials	No. AE	No. *Related AE	with DLT
Autologous	40	847	2	11	8	0
DC	27	466	0	0	0	0
Tumor	13	381	2	11	8	0
Allogeneic	(5)	130	3	20	5	1
Synthetic	83	2008	17	67	27	2
Peptide	36	852	7	10	7	0
DNA	12	208	1	1	1	0
Virus	26	592	7	47	17	0
Bacteria	4	81	4	27	7	2
Anti-idiotypic	8	339	1	7	0	0
Liposomal	1	17	1	2	2	0
TOTAL	127	2985	22	98	40	3

### Trials with DLT

Trial	Vaccine	Toxicity	DLT
Dols et al. 2003	Allogeneic HER2/neu(+) breast cancer cells (SC) with GM-CSF or BCG	Nausea/Vom iting	1 patient at 250 μg/m2 GM-CSF
Maciag et al. 2009	L. monocytogenes secreting HPV-16 E7 fused to Lm listeriolysin O (IV)	Hypotension	3 patients at highest dose level
Guthmann et al. 2004	GM3 ganglioside with N. meningitidis outer membrane (IM)	Hypotension	1 patient at highest dose level

### **Conclusion**

• Dose escalation design has no role in defining

-The maximum tolerated dose (MTD)

Except for bacterial vector vaccines

## Does dose escalation determine BAD?

Vaccine Category	No. Trials	Dose Related Cellular Immune Response
Autologous	32	0
Allogeneic	4	0
Synthetic	80	0
Total	116	0

### **Conclusion**

 Dose escalation design has not been shown to define

- Tolerability (except for bacterial vector vaccines)
- -Biologically active dose (BAD)

### **Conclusion**


 Dose escalation design has not been shown to define

- Tolerability (except for bacterial vector vaccines)
- -Biologically active dose (BAD)

A new design paradigm is needed

#### **Alternative Clinical Trial Design For Cancer Vaccine**

#### Step 1. Determining a starting dose of a vaccine



## How do we determine a starting dose of a vaccine?

Class used before & NON-TOXIC (e.g., peptide)

Class used before & NON-TOXIC (e.g., peptide)



Use Immune Active Dose

Class used before & NON-TOXIC (e.g., peptide)



Use Immune Active Dose

Used before – TOXIC Expected to be toxic (e.g., bacterial vector)

Class used before & NON-TOXIC (e.g., peptide)



Use Immune Active Dose

Used before – TOXIC Expected to be toxic (e.g., bacterial vector)



Traditional phase 1 trial

Not used before & not expected to be toxic

Not used before
& not expected to be toxic

One Patient Escalation Design (OPED)

Not used before & not expected to be toxic

One Patient Escalation Design (OPED)

**Dose Determination** 

Not used before & not expected to be toxic

One Patient Escalation Design (OPED)

Dose Determination

One patient per tested dose is treated until an immune response is induced (IAD)

Not used before & not expected to be toxic

One Patient Escalation Design (OPED)

**Dose Determination** 

One patient per tested dose is treated until an immune response is induced (IAD)

**Dose Confirmation** 

Not used before & not expected to be toxic

One Patient Escalation Design (OPED)

**Dose Determination** 

One patient per tested dose is treated until an immune response is induced (IAD)

**Dose Confirmation** 

Expand IAD one patient at a time up to 7 pts until achieving an additional immune response

Not used before & not expected to be toxic

One Patient Escalation Design (OPED)

**Dose Determination** 

One patient per tested dose is treated until an immune response is induced (IAD)

**Dose Confirmation** 

Expand IAD one patient at a time up to 7 pts until achieving an additional immune response

If no additional immune response in 7 patients, stop adding patients and continue escalation of one patient at a time.

#### **Alternative Clinical Trial Design For Cancer Vaccine**

#### Step 1. Determining a starting dose of a vaccine

